InnoCare Pharma Limited (HKG:9969)

Market Cap	26.41B +41.9%
Revenue (ttm)	2.64B +135.3%
Net Income	714.94M
EPS	n/a
Shares Out	1.70B
PE Ratio	36.94
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,194,540
Average Volume	6,900,732
Open	12.30
Previous Close	12.40
Day's Range	12.12 - 13.24
52-Week Range	6.89 - 20.62
Beta	0.59
RSI	61.63
Earnings Date	Mar 25, 2026

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 1,176
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9969

Financial Performance

Financial numbers in CNY